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7RESEARCH Open AccessLate toxicity and five year outcomes after
high-dose-rate brachytherapy as a monotherapy
for localized prostate cancer
Pirus Ghadjar1*, Sebastian L Oesch2, Cyrill A Rentsch3, Bernhard Isaak2, Nikola Cihoric2, Peter Manser2,
George N Thalmann4 and Daniel M Aebersold2Abstract
Background: To determine the 5-year outcome after high-dose-rate brachytherapy (HDR-BT) as a monotherapy.
Methods: Between 10/2003 and 06/2006, 36 patients with low (28) and intermediate (8) risk prostate cancer were
treated by HDR-BT monotherapy. All patients received one implant and 4 fractions of 9.5 Gy within 48 hours for a total
prescribed dose (PD) of 38 Gy. Five patients received concomitant androgen deprivation therapy (ADT). Toxicity was
scored according to the common terminology criteria for adverse events from the National Cancer Institute (CTCAE)
version 3.0. Biochemical recurrence was defined according to the Phoenix criteria and analyzed using the Kaplan Meier
method. Predictors for late grade 3 GU toxicity were analyzed using univariate and multivariate Cox regression analyses.
Results: The median follow-up was 6.9 years (range, 1.5-8.0 years). Late grade 2 and 3 genitourinary (GU) toxicity
was observed in 10 (28%) and 7 (19%) patients, respectively. The actuarial proportion of patients with late grade 3
GU toxicity at 5 years was 17.7%. Late grade 2 and 3 gastrointestinal (GI) toxicities were not observed. The crude
erectile function preservation rate in patients without ADT was 75%. The 5 year biochemical recurrence-free survival
(bRFS) rate was 97%. Late grade 3 GU toxicity was associated with the urethral volume (p = 0.001) and the urethral
V120 (urethral volume receiving ≥120% of the PD; p = 0.0005) after multivariate Cox regression.
Conclusions: After HDR-BT monotherapy late grade 3 GU was observed relatively frequently and was associated
with the urethral V120. GI toxicity was negligible, the erectile function preservation rate and the bRFS rate was excellent.
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High-dose-rate brachytherapy (HDR-BT) offers the direct
application of high doses to the prostate while sparing the
surrounding bladder and rectum. It has also advantages
over the permanent seed implantation (seeds or low-dose
rate brachytherapy) regarding radiation safety and HDR-BT
thus gained popularity both as a boost combined with
additional external beam radiotherapy or as a monotherapy
for localized prostate cancer.
Several groups have described their HDR-BT mono-
therapy experience [1-9], however less is known about the
outcomes after longer follow-up. We therefore performed* Correspondence: pirus.ghadjar@charite.de
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unless otherwise stated.an up-date of our previously reported HDR-BT monother-
apy cohort [9].Methods
Patient selection and characteristics
A total of 41 patients with histologically proven adenocar-
cinoma of the prostate treated by HDR-BT as a monother-
apy were retrospectively analyzed. The pre-treatment
staging included a complete history, physical examination,
digital rectal examination, transrectal ultrasound (TRUS)
of the prostate, biopsy with specification of the Gleason
score, pre-treatment prostate-specific antigen (PSA) level,
computed tomography (CT) and/or magnetic resonance
imaging (MRI) of the abdomen and pelvis as previously
reported [9]. In the presence of bone pain a bone scan was
performed. The indication for HDR-BT as a monotherapyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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similar to criteria for low-dose-rate (LDR) seeds brachyther-
apy. Risk of recurrence was determined according to the
National Comprehensive Cancer Network practice guide-
lines in oncology (www.nccn.org): Low risk being T1-T2a,
Gleason score ≤6, PSA <10 ng/mL and intermediate risk
being T2b-T2c or, Gleason score 7 or PSA 10–20 ng/mL.
Patients with prior pelvic radiation (n = 1) and genitouri-
nary (GU) morbidity ≥ grade 2 prior to radiation (n = 4)
were excluded from further analysis. The remaining 36
patients, treated between October 2003 and June 2006,
comprised the study population.
This study was approved by the institutional ethics
committee of the Bern University Hospital.
Androgen deprivation therapy
A total of 5 patients (14%) received androgen deprivation
therapy (ADT) of which 3 were low and 2 were intermedi-
ate risk patients. ADT was initiated in all 5 patients by the
referring urologist at their descretion for concommittant
treatment. ADT was always given before and during
brachytherapy, with a median total duration of 7 months
(range, 3–33 months). One patient received combined
androgen blockade consisting of antiandrogen and a go-
nadotropin releasing hormone analogue. Four patients
received antiandrogen monotherapy.
Brachytherapy implant
All patients received one implant and four separate
fractions of HDR-B, with a minimal interval of 6 hours
delivered within 48 hours. Fraction dose was 9.5 Gy,
the total prescribed dose (PD) was 38 Gy, as previously
described [9]. For the implantation of the applicators,
patients underwent spinal anesthesia and were positioned
in lithotomy position. The applicators were implanted
transperineally by an urologist under real-time TRUS
guidance using a template for parallel needle insertion.
Patients received a variable number of needles, median
13 (range, 10–18) depending on the prostate size and
configuration. Axial cross sections were acquired in
5 mm steps and transferred to the Plato® treatment
planning software V14.2. (Nucletron, an Elektra company
(Elektra AB, Stockholm, Sweden)). Dose optimization was
done on the reconstructed applicator geometry using
dose point and manual optimization algorithms. A typical
ultrasound image of the applicator geometry is provided
in Figure 1. Before radiation, patients received 2–3 gold
markers (diameter: 0.9 mm, length: 7 mm), implanted
under TRUS guidance, which were used for assessment
of inter-fraction needle motion, assessed by pelvic x-ray
before each fraction. In case of dislocation all applicators
were repositioned before the next fraction until complete
agreement was found with the reference x-ray. A video
capture software (Nucletron) was used to transfer theUS images to the Plato® treatment planning software.
The prostate gland and the organs at risk (OAR) i.e.
prostatic urethra and rectum were contoured. The dose to
the rectum and urethra was evaluated using dose volume
histogram (DVH). The contouring of the urethra and the
rectum was based on the ultrasound image: the urethra
was delineated from the apex of the prostate to the base
of the bladder, the rectum was defined as the rectum sector
on the ultrasound image along the planning target volume
(PTV) including the muscularis propria.
The prostate without safety margins was defined as
the PTV. Based on DVH analysis, the quality of plans
and implants was evaluated using the following indicators:
The PTV V100 (% of PTV receiving ≥100% of the PD)
and D90 (dose delivered to 90% of the PTV), both of
which were recorded. To assess dose exposure of OAR,
the absolute values of V70, V80 of the rectum and V100,
V120, V125, V150 of the prostatic urethra were determined
(volume of the OAR that received a dose ≥70%, 80% or
100%, 120%, 125%, 150% of the PD, respectively). Add-
itionally, the maximum dose D1 of the rectum and urethra
(defined as the dose that encompass ≥ 1% of the rectal or
urethral volume) and the number of needles used was re-
corded. The dosimetry optimization goals were to achieve
a most conformal as possible coverage of the prostate tak-
ing into consideration sometimes an under dosage in apex
and base regions and at the same time optimizing the
dwell times to prevent locally very high dose values. A
hard constraint was: PTV V100 > 90%. The max dose on
the rectum was required to be less then 80% (V80 = 0) of
the prescribed dose and the maximal dose for the urethra
less than 150% (V150 = 0) of the prescribed dose. The total
dose was prescribed to the 100% isodose covering the
PTV. A high-dose-rate afterloading system (Nucletron)
with a 192Ir stepping source was used.
Follow-up protocol
Follow-up visits were arranged 2–4 weeks after completion
of HDR-BT and every 3 to 6 months for the first 2 years
and annually thereafter with a digital rectal examination
and a serum PSA level obtained at each visit. Patients alter-
nated follow-up visits between their urologist and radiation
oncologist. None of the patients were lost to follow-up.
Toxicity scoring
The symptoms dysuria, incontinence, retention, frequency/
urgency, hematuria, diarrhea, rectal pain and rectal
bleeding were graded using the common terminology
criteria for adverse events from the National Cancer
Institute (CTCAE version 3.0). Erectile dysfunction (ED)
was scored based on clinical symptoms as follows: grade
0 = no symptoms of ED; grade 1 = decreased erectile
function but still able to perform sexual intercourse;
grade 2 = decreased erectile function not able to perform
Figure 1 A typical ultrasound image of the applicator geometry used in HDR-BT. The red line represents the prostate or the planning
target volume (PTV), respectively. Urethra and anterior rectal wall are depicted in yellow. The isodose lines are 50% = dark blue; 85% = purple;
100% = light blue; 150% = orange; 200% =white.
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defined as symptoms who increased over baseline and
occurred within 3 months after the end of treatment. Late
toxicity at last follow-up visit was noted and termed
“last late toxicity”; this was done to assess whether the
late toxicity was persistent or was transient.
Biochemical failure
Biochemical recurrence-free survival (bRFS) was assessed
according to the Phoenix criteria, defining a biochem-
ical failure as a PSA rise of 2 ng/mL or more above the
nadir PSA.
Statistical analysis
Descriptives include absolute and relative frequencies for
categorical variables and the median and interquartile
range (IQR) for quantitative variables.The primary objective was the occurrence of late grade 3
GU toxicity and secondary objectives included bRFS and
late gastrointestinal (GI) toxicity. Late GU toxicity (grade
0–2 vs. grade 3) was grouped according to the number of
grade 3 events observed and compared with clinical and
dosimetric factors using univariate and multivariate Cox re-
gression analyses. Actuarial toxicity-free survival and bRFS
rates were calculated using the Kaplan Meier method. Stat-
istical significance was considered on a two-sided signifi-
cance level (α) of = 0.05. Statistical analysis was performed
with SPSS® version 19.0 (SPSS Inc., Chicago, IL).
Results and discussion
Patient characteristics are summarized in Table 1. The
pre-implant prostate size was 40 cm3 (range, 24–62 cm3),
however this information was only available for 17/36
patients. Dosimetric characteristics are summarized in
Table 1 Patient characteristics
Total patients (n = 36)
Age, median (IQR), years 63 (10)
Tumor classification
cT1 27 (75.0%)
cT2 9 (25.0%)
Gleason Score
3-5 8 (22.2%)
6 23 (63.9%)
7 5 (13.9%)
Pre-treatment PSA
≤10 ng/mL 31 (86.1%)
>10 ng/mL 5 (13.9%)
Percent positive biopsies
≤ 50% 17 (47.2%)
> 50% 14 (38.9%)
Unknown 5 (13.9%)
Risk group
Low 28 (77.8%)
Intermediate 8 (22.2%)
Abbreviations: PSA prostate-specific antigen, IQR interquartile range.
Table 3 Late genitourinary toxicity
Late† Last late§
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1.5–8.0 years).Symptom Grade n (%) n (%)
Dysuria 0 23 (64) 36 (100)
1 8 (22) 0 (0)
2 5 (14) 0 (0)
Incontinence 0 29 (81 ) 33 (92)
1 7 (19) 3 (8)
Retention 0 19 (53) 27 (75)
1 3 (9) 6 (17)
2 7 (19) 3 (8)Late genitourinary and gastrointestinal toxicity
Baseline symptoms, acute toxicity and early late toxicity
was previously described. Regarding GU baseline symp-
toms, these were completely absent in around 53%, and
were of grade 1 in 47% of the patients. GI baseline
symptoms were absent in around 91% and of grade 1
and 2 in 3% and 6% of the patients, respectively [9]. Late
GU toxicity was of grade 2 in 10 (28%) and of grade 3 inTable 2 Dosimetric characteristics
Dosimetric measure Mean (SD) Median (IQR)
PTV V100 (%) 93.5 (5.7) 95.5 (8.7)
PTV D90 (Gy) 38.8 (7.3) 41.2 (5.3)
Urethra V100 (cm
3) 0.46 (0.18) 0.44 (0.18)
Urethra V120 (cm
3) 0.16 (0.14) 0.15 (0.23)
Urethra V125 (cm
3) 0.08 (0.09) 0.03 (0.14)
Urethra V150 (cm
3) 0.0 (0.0) 0.0 (0.0)
Rectal V70 (cm
3) 0.1 (0.1) 0.08 (0.005)
Rectal V80 (cm
3) 0.006 (0.02) 0.00 (0.005)
Abbreviations: IQR interquartile range, PTV planning target volume, PTV V100
percentage of PTV receiving ≥100% of prescribed dose, D90 dose administered
to 90% of the PTV, urethral V100-V150 absolute urethral volume that received a
dose ≥100%, 120%, 125%, 150% of the prescribed dose, rectal V70-V80 absolute
rectal volume that received a dose ≥70% or 80%, of the prescribed dose.7 (19%) (Table 3). The median time from RT completion
to the occurrence of late grade 3 GU toxicity was
77 months (IQR, 41.45 months). The 5 year probability
of late grade 3 GU toxicity was 17.7% (Figure 2A). All 7
patients who developed late grade 3 GU toxicity under-
went an urological intervention. Six patients had a bulbar
urethral stricture requiring urethral dilatation, in 4 patients
an additional TUR-P was performed. The remaining patient
presented with acute urinary retention and received a foley
catheter and underwent a TUR-P shortly thereafter. Late
GU toxicity decreased as time from treatment completion
elapsed. At the last follow-up visit late grade 3 GU toxicity
was not observed (Table 3).
No patient had late grade 2 or 3 GI toxicity at the last
follow-up visit all grade 1 late GI toxicities were amelio-
rated (Table 4).
Factors associated with genitourinary toxicity
There was no association between late ≥ grade 2 GU
toxicity and clinical or dosimetric factors. However the
occurrence of late grade 3 GU toxicity was associated
with clinical and dosimetric variables after univariate
Cox regression analysis (Table 5). Late grade 3 GU toxicity
was associated with the urethral volume (p = 0.001) and3 7 (19) 0 (0.0)
Frequency/urgency 0 16 (44) 25 (70)
1 13 (36) 7 (19)
2 6 (17) 4 (11)
3 1 (3) 0 (0.0)
Hematuria 0 28 (78) 34 (94)
1 4 (11) 1 (3)
2 4 (11) 2 (3)
Highest GU* 0 11 (31) 21 (58)
1 8 (22) 9 (25)
2 10 (28) 6 (17)
3 7 (19) 0 (0)
Abbreviations: GU genitourinary, *The highest toxicity in a patient was counted
as a single event, †> 3 months after completion of therapy,
§Incidence of late toxicity at last follow-up visit.
Figure 2 Kaplan Meier plots showing the probability of late grade 3 genitourinary toxicity for all patients (A) and stratified according
to the urethral V120 (B).
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Table 4 Late gastrointestinal toxicity
Late† Last late§
Symptom Grade n (%) n (%)
Diarrhea 0 33 (92) 36 (100)
1 3 (8) 0 (0)
2 0 (0) 0 (0)
Rectal pain 0 36 (100) 36 (100)
1 0 (0.0) 0 (0.0)
Rectal bleeding 0 36 (100) 36 (100)
1 0 (0) 0
Highest GI* 0 33 (92) 36 (100)
1 3 (8) 0 (0)
2 0 (0) 0 (0)
Abbreviations: GI gastrointestinal, *The highest toxicity in a patient was
counted as a single event, †> 3 months after completion of therapy, §Incidence
of late toxicity at last follow-up visit.
Ghadjar et al. Radiation Oncology 2014, 9:122 Page 6 of 8
http://www.ro-journal.com/content/9/1/122the urethral V120 (urethral volume receiving ≥120% of
the prescribed dose; p = 0.0005) after multivariate Cox
regression (Table 4). The quartiles for the urethral V120
were 25% = 0.02 cm3; 50% = 0.15 cm3 and 75% = 0.25 cm3.
The probability of late grade 3 GU toxicity stratified to theTable 5 Univariate and multivariate associations with late gra
Variables Associated level
Univariate analysis
Age (years) Continuous
Risk group* Intermediate
Prostate volume# Continuous
Number of Applicators Continuous
PTV volume (cm3) Continuous
PTV V100 (%) Continuous
PTV D90 (Gy) Continuous
Urethral volume (cm3) Continuous
Urethral D1 (Gy) Continuous
Urethral V100 (cm
3) Continuous
Urethral V120 (cm
3) Continuous
Urethral V125 (cm
3) Continuous
Acute grade 3 GU toxicity Yes
Multivariate analysis
Urethral volume (cm3) Continuous
Urethral V100 (cm
3) Continuous
Urethral V120 (cm
3) Continuous
Acute grade 3 GU toxicity Yes
Abbreviations: GU genitourinary, PTV planning target volume, PTV V100 percentage o
the PTV, Urethral V100-V150 absolute urethral volume that received a dose ≥100%, 12
encompass 1% of the urethral volume, *according to the National Comprehensive C75% quartile of the urethral V120 is depicted in Figure 2B.
Significant correlations between the urethral V100, V120
and V125 and increased PTV V100 and D90, respectively
have previously been described [9].
Erectile function
Of the 31 patients who did not receive ADT, 20 (65%)
had no symptoms of ED before treatment and 8 (26%)
had decreased erectile function but were still able to
perform sexual intercourse. The remaining three patients
had decreased erectile function and were unable to per-
form intercourse. At the latest follow-up visit 21 of these
28 patients (75%) were able to perform intercourse. Thus,
the erectile function preservation rate was 75% in pa-
tients without ADT. Of these 21 sexually active men 7
patients received oral therapy with a phosphodiesterase
type 5 inhibitor.
Biochemical outcome
During follow-up one patient with low-risk disease who
did not receive ADT experienced biochemical recurrence
after 56 months. The 5 year bRFS according to the Phoenix
criteria was 97%. Overall the median PSA nadir value was
0.1 ng/mL (IQR, 0.235 ng/mL) and time to nadir wasde 3 genitourinary toxicity
Late grade 3 GU toxicity
Hazard ratio (95% CI) p-value
1.031 (0.921-1.154) 0.596
0.659 (0.079-5.481) 0.699
0.928 (0.835-1.032) 0.170
1.247 (0.906-1.718) 0.176
1.014 (0.974-1.056) 0.504
>1000 (0.000- > 1000) 0.371
83.476 (0.019- > 1000) 0.301
41.143 (2.754-614.621) 0.007
6.946 (0.000- > 1000) 0.692
183.29 (6.785- > 1000) 0.002
926.461 (2.653- > 1000) 0.022
405.747 (0.249- > 1000) 0.111
7.846 (0.876-70.307) 0.066
338.940 (9.502- > 1000) 0.001
-
5778.111 (14.398- > 1000) 0.005
-
f PTV receiving ≥100% of prescribed dose, D90 dose administered to 90% of
0%, 125%, 150% of the prescribed dose, Urethral D1 maximal dose that
ancer Network (NCCN), #pre-treatment, ADT androgen deprivation therapy.
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patients died, both in the absence of biochemical recur-
rence, thus the crude overall survival rate was 94%.
This report describes the 5-year late toxicity and bRFS
outcome, based on a median follow-up of almost seven
years, in association with DVH parameters in patients
with low and intermediate risk prostate cancer treated
by HDR-BT monotherapy.
We are aware of 5 cohorts of patients treated by
HDR-BT as a monotherapy using more than 3 fractions
and reporting on late toxicity and biochemical control
data (Table 6) [1-5].
Meanwhile, further reports on extreme HDR-BT hypo-
fractionation using only 3 [6] 2 [7] or only 1 fraction [8]
became available with promising results regarding cancer
control and acute and early late toxicity. However, due to
their relatively short median follow-up of < 40 months,
these results must be regarded as preliminary.
Compared to the mentioned literature the biochemical
control rate of 97% in our low-intermediate-risk patient
cohort was excellent, the erectile function preservation
rate of 75% after almost 7 years of follow-up was en-
couraging and late GI toxicity was negligible. However
the observed late GU grade 2 and 3 toxicity rates of 28
and 19% were in the upper range of published studies.
Remarkably, some of the grade 2 events were transient
and resolved until the end of follow-up were the inci-
dence of late grade 2 toxicity was 17%. Moreover, all
grade 3 events were successfully managed by urethral
dilatation followed by a TUR-P in 4 of 6 cases. We
found an association between late grade 3 toxicity and the
urethral V120 after multivariate analysis. The association be-
tween the dose to the prostatic urethra and the occurrence
of bulbar urethral strictures might be indirectly caused by
radiation of vascular support of the urethra. UncertaintiesTable 6 Study results on HDR-BT as a monotherapy using mo
Study (reference) n M. follow-up
(vrs)
Risk HDR schedule AD
Demanes (1) 298 5.2 L 81%, I 18%,
H 1%
6 × 7 Gy (53%) 24%
4 × 9.5 Gy (47%)
Zamboglou (2) 718 4.4 L 55%, I 25%,
H 20%
4 × 9.5 Gy (68%) 21.
3 × 11.5 Gy (32%)
Yoshioka (3) 112 5.4 L 13%, I 26%,
H 61%
9 × 6 Gy 84%
Hoskin (4) 197 0.5-5 L 4%, I 52%,
H 44%
4 × 8.5 Gy (15%) 80%
4 × 9 Gy (13%)
3 × 10.5 Gy (55%)
2 × 13 Gy (17%)
Rogers (5) 284 2.7 I 100% 6 × 6.5 Gy 16%
Present study 36 6.9 L 78%, I 22% 4 × 9,5 Gy 14%
Abbreviations: M median, G grade, GU genitourinary, GI gastrointestinal, L low, I inte
*according to the Phoenix criteria, #genitourinary and gastrointestinal toxicity not dof the delineation of the urethra without use of hydrogel
might also have contributed to excess dose to the urethra.
We used only one implant for the 4 fractions applied
over 2 days and controlled interfractional movement of
the applicators using pre-implanted gold markers and
orthogonal conventional X-rays. As previously described
significant applicator shifts were detected and corrected
and these shifts were not associated with the occurrence
of GU toxicity [10]. However, we cannot exclude that
some applicator shifts were not recognized contributing
to impaired dosimetry and subsequently late GU toxicity.
Also, during planning the rectal ultrasound probe was
in place with legs up in lithotomy position while treat-
ment was delivered with legs straight and without ultra-
sound probe which has been described as unfeasible by
others [11]. The conduction of 2 separate implants might
reduce late GU toxicity and improved image-guided pro-
cedures in brachytherapy could help to limit these effects,
in future. Moreover, patients were not assessed with the
International Prostate Symptom Score (IPSS) at baseline.
It might be that exclusion of patients with significant base-
line symptoms according to the IPSS would have reduced
the need for urological interventions in our cohort. Also
the use of Cox regression analysis is limited because of the
small sample size and low number of events. As a note of
caution, we have also to emphasize that the median
follow-up time of present study is the longest reported
so far. It might well be, that the grade 3 toxicities will
increase in other patients cohorts with longer follow-up
time. Additionally, it must be acknowledged that most of
the low-risk patients in our cohort might alternatively
have been treated by an active surveillance approach
which might be associated with comparable tumor control
rates but less GU toxicity [12] – a concept, however,
which was not well established at that time.re than 3 fractions
T Toxicity
score
G2 GI late
toxicity
G3 GI late
toxicity
G2 GU late
toxicity
G3 GU late
toxicity
bRFS*
CTCAE 3.0 <1% <1% 10% 3% 97%
4% CTCAE 3.0 ~1% 1.6% ~20% 3.5% 94%
CTCAE 3.0 12%# 3%# 12%# 3%# 83%
RTOG 1% 4-13% 20-30% 3-14% 95%
RTOG 0% 0% 1.8% 0.7% 83%
CTCAE 3.0 0% 0% 28% 19% 97%
rmediate, H high, bRFS biochemical recurrence-free survival,
iscriminated.
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Late grade 3 GU toxicity occurred in 19% of patients.
Proper patient selection, reduction of urethral dose
(V120 below 0.25 cm3) along with a rigourous quality
management including proper replanning or even on-
line planning at each fraction might reduce this rate.
Late GI toxicity after this treatment was negligible and
the erectile function preservation rate and the 5 year
bRFS was excellent.
Abbreviations
HDR-BT: High-dose-rate brachytherapy; PD: Prescribed dose; ADT: Androgen
deprivation therapy; GU: Genitourinary; GI: Gastrointestinal; bRFS: Biochemical
recurrence-free survival; TRUS: Transrectal ultrasound; CT: Computed
tomography; MRI: Magnetic resonance imaging; GnRH: Gonadotropin
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